Martin Knight BSc, Author at Insights From Our Labs to Yours

Inflammatory Bowel Disease clinical studies and the importance of patient centricity

by Martin Knight BScupdated on Monday, June 7, 2021Tuesday, June 9, 2020

In today’s exceptionally crowded clinical trial environment of inflammatory bowel disease (IBD), patient-centric practices can help your study of Crohn’s disease (CD) or ulcerative colitis (UC) stand out to both patients and sites. Learn about your options to increase your trial’s patient centricity, encourage recruitment and promote ongoing patient retention. …

Minimizing placebo effect in inflammatory bowel disease clinical studies

by Martin Knight BScupdated on Tuesday, June 9, 2020Thursday, January 16, 2020

With 93 Crohn’s Disease (CD) and 168 Ulcerative Colitis (UC) Phase I-III industry-sponsored studies planned and open to enrollment, there is a significant focus on research into new therapies for inflammatory bowel disease (IBD)1. Remission is the main aim of IBD therapy, but IBD studies often face challenges with minimizing …

Attracting Naïve Patients to RA Clinical Studies

Finding the Other 90%: Attracting Naïve Patients to RA Studies

by Martin Knight BScupdated on Thursday, May 20, 2021Thursday, May 25, 2017

A recent study by Tufts Center for the Study of Drug Development, based on a survey of 2,000 physicians and nurses primarily in the United States and Europe, found that 91% of physicians feel ‘somewhat’ or ‘very’ comfortable discussing the opportunity to participate in a clinical trial with patients, but …